<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02006472</url>
  </required_header>
  <id_info>
    <org_study_id>TV7820-CNS-20002</org_study_id>
    <secondary_id>2013-001888-23</secondary_id>
    <nct_id>NCT02006472</nct_id>
  </id_info>
  <brief_title>A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease</brief_title>
  <official_title>A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prilenia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Huntington's Disease Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huntington Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prilenia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multinational, randomized, parallel-group, double-blind,&#xD;
      placebo-controlled, dose range finding study to compare the efficacy and safety of different&#xD;
      doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's&#xD;
      Disease (HD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Originally, the study was designed to assess the effect of pridopidine on motor function at&#xD;
      26 weeks. Due to the recognition that the primary target of pridopidine is the Sigma-1&#xD;
      receptor, the trial was extended from 26 to 52 weeks to evaluate the effect of pridopidine on&#xD;
      Total Functional Capacity (TFC). A minimum of 52 weeks are needed for the placebo group to&#xD;
      decline and allow a window to assess an effect on TFC (a prespecified endpoint).&#xD;
      Approximately 20% of patients completed 26 weeks of the study before IRB approvals for this&#xD;
      extension, and did not continue into the 2nd treatment period up to 52 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2014</start_date>
  <completion_date type="Actual">July 7, 2016</completion_date>
  <primary_completion_date type="Actual">December 16, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 15 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124. Negative change from baseline values indicate improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Total Functional Capacity (TFC) at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>Pridopidine 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pridopidine 67.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pridopidine 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pridopidine 112.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pridopidine</intervention_name>
    <description>22.5 mg and 45 mg capsules</description>
    <arm_group_label>Pridopidine 112.5 mg</arm_group_label>
    <arm_group_label>Pridopidine 45 mg</arm_group_label>
    <arm_group_label>Pridopidine 67.5 mg</arm_group_label>
    <arm_group_label>Pridopidine 90 mg</arm_group_label>
    <other_name>TV7820</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules matching drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pridopidine 112.5 mg</arm_group_label>
    <arm_group_label>Pridopidine 45 mg</arm_group_label>
    <arm_group_label>Pridopidine 67.5 mg</arm_group_label>
    <arm_group_label>Pridopidine 90 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of HD based on the presence of &gt;/= 36 CAG repeats&#xD;
&#xD;
          -  Male or female age ≥21 years, with an onset of HD after 18 years' old.&#xD;
&#xD;
          -  Females of childbearing potential must be compliant in using adequate birth control&#xD;
             throughout the duration of the study&#xD;
&#xD;
          -  Body weight ≥50 kg&#xD;
&#xD;
          -  Sum of &gt;= 25 points on the UHDRS-TMS and UHDRS Independence Score &lt;=90%&#xD;
&#xD;
          -  Able and willing to provide written informed consent prior to any study related&#xD;
             procedure.&#xD;
&#xD;
          -  Willing to provide a blood sample for genetic analyses&#xD;
&#xD;
          -  Willing and able to take oral medication and able to comply with the study specific&#xD;
             procedures.&#xD;
&#xD;
          -  Ambulatory, being able to travel to the study center, and judged by the investigator&#xD;
             as likely to be able to continue to travel for the duration of the study.&#xD;
&#xD;
          -  Availability and willingness of a caregiver, informant or family member to accompany&#xD;
             the patient to the clinic at study, and the suitability of the caregiver should be&#xD;
             judged by the Investigator.&#xD;
&#xD;
               -  Other criteria apply, please contact the investigator for more information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically significant heart disease at the screening visit&#xD;
&#xD;
          -  Treatment with tetrabenazine within 6 weeks of study screening&#xD;
&#xD;
          -  Patients with a history of epilepsy or of seizures within the last 5 years&#xD;
&#xD;
          -  Have other serious medical illnesses in the opinion of the investigator may put the&#xD;
             patient at risk when participating in the study or may influence the results of the&#xD;
             study or affect the patient's ability to take part in the study&#xD;
&#xD;
          -  Patients receiving medications (within the last 6 weeks prior to screening) that have&#xD;
             been proven to prolong QT interval or who may require such medications during the&#xD;
             course of the study such as but not limited to non allowed anti psychotic medications,&#xD;
             tricyclic antidepressants and/or Class I antiarrhythmics&#xD;
&#xD;
               -  Other criteria apply, please contact the investigator for more information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational Site 12199</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12204</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12201</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12196</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12207</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12202</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12206</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12200</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12203</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12198</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12211</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12205</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12209</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12208</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12210</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12197</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 78055</name>
      <address>
        <city>Caulfield South</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 78056</name>
      <address>
        <city>Kew</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 78058</name>
      <address>
        <city>Subiaco</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 78057</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 33021</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 33027</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 11035</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 11037</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 11036</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 39028</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 39027</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 35123</name>
      <address>
        <city>Angers cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 35122</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 35125</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 35124</name>
      <address>
        <city>Marseille Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 35121</name>
      <address>
        <city>Salouel</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 35165</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 32408</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 32410</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 32409</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 32407</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 30083</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 30080</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 30082</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 30081</name>
      <address>
        <city>Pozzilli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 30084</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 38059</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 53150</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 53149</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 53148</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 53151</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 50215</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 50213</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 50214</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 34058</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 34054</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 34059</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 34056</name>
      <address>
        <city>Headington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 34060</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 34055</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 34061</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 34057</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. J Huntingtons Dis. 2020;9(4):371-380. doi: 10.3233/JHD-200440.</citation>
    <PMID>33164941</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <results_first_submitted>March 14, 2021</results_first_submitted>
  <results_first_submitted_qc>July 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2021</results_first_posted>
  <disposition_first_submitted>May 8, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 8, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 11, 2018</disposition_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington's Disease</keyword>
  <keyword>Pridopidine</keyword>
  <keyword>Pride-HD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 492 patients were screened; of these, 408 were randomized. The main reason for not randomizing patients was noncompliance with the eligibility criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of placebo matching pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to the randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="P2">
          <title>Pridopidine 45 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="P3">
          <title>Pridopidine 67.5 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="P4">
          <title>Pridopidine 90 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="P5">
          <title>Pridopidine 112.5 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Through Week 26)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (Through Week 52)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Treatment in Period 2</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat: all patients randomized into the study</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of placebo matching pridopidine 22.5 mg or matching placebo and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="B2">
          <title>Pridopidine 45 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="B3">
          <title>Pridopidine 67.5 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="B4">
          <title>Pridopidine 90 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="B5">
          <title>Pridopidine 112.5 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="82"/>
            <count group_id="B4" value="81"/>
            <count group_id="B5" value="82"/>
            <count group_id="B6" value="408"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="11.34"/>
                    <measurement group_id="B2" value="51.9" spread="11.75"/>
                    <measurement group_id="B3" value="51.0" spread="11.83"/>
                    <measurement group_id="B4" value="51.3" spread="12.69"/>
                    <measurement group_id="B5" value="47.5" spread="11.40"/>
                    <measurement group_id="B6" value="50.4" spread="11.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of neuroleptics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CYP2D6 genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Poor metaboliser</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extensive metaboliser</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate metaboliser</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ultra-rapid metaboliser</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Cytosine-Adenosine-Guanine (CAG) Repeats</title>
          <units>Number of CAG repeats</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="3.23"/>
                    <measurement group_id="B2" value="44.1" spread="4.12"/>
                    <measurement group_id="B3" value="45.0" spread="4.73"/>
                    <measurement group_id="B4" value="44.5" spread="4.90"/>
                    <measurement group_id="B5" value="45.3" spread="3.66"/>
                    <measurement group_id="B6" value="44.7" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26</title>
        <description>TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 15 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124. Negative change from baseline values indicate improvement.</description>
        <time_frame>26 weeks</time_frame>
        <population>Full analysis set (FAS) i.e. patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of placebo matching pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Pridopidine 45 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Pridopidine 67.5 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Pridopidine 90 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O5">
            <title>Pridopidine 112.5 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26</title>
          <description>TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 15 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124. Negative change from baseline values indicate improvement.</description>
          <population>Full analysis set (FAS) i.e. patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.79" spread="0.99"/>
                    <measurement group_id="O2" value="-3.37" spread="1.05"/>
                    <measurement group_id="O3" value="-3.09" spread="1.02"/>
                    <measurement group_id="O4" value="-4.13" spread="1.00"/>
                    <measurement group_id="O5" value="-2.74" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3202</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>4.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2266</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6348</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.07</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1447</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <time_frame>52 weeks</time_frame>
        <population>Safety Analysis set, i.e. patients who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of pridopidine 22.5 mg or matching placebo and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Pridopidine 45 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg (or matching placebo) and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Pridopidine 67.5 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg (or matching placebo) and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Pridopidine 90 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg (or matching placebo) and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O5">
            <title>Pridopidine 112.5 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg (or matching placebo) and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <population>Safety Analysis set, i.e. patients who received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Total Functional Capacity (TFC) at Week 52</title>
        <description>The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full analysis set (FAS) i.e. patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of placebo matching pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Pridopidine 45 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Pridopidine 67.5 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Pridopidine 90 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O5">
            <title>Pridopidine 112.5 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Functional Capacity (TFC) at Week 52</title>
          <description>The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.</description>
          <population>Full analysis set (FAS) i.e. patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.20"/>
                    <measurement group_id="O2" value="0.04" spread="0.22"/>
                    <measurement group_id="O3" value="-0.72" spread="0.21"/>
                    <measurement group_id="O4" value="-0.65" spread="0.20"/>
                    <measurement group_id="O5" value="-0.59" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7042</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5099</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4061</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change in Total Functional Capacity (TFC) From Baseline in Patients With Early HD (Defined as Patients With TFC&gt;=7)</title>
        <description>The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.</description>
        <time_frame>52 weeks</time_frame>
        <population>FAS i.e. pts receiving ≥1 dose of study drug and with ≥1 post-BL efficacy assessment; pts with early HD defined by BL TFC score ≥7.&#xD;
The study tested 4 pridopidine doses on TMS for 26 w. Due to a new understanding on pridopidine's mechanism of action (S1R agonist), the study was extended to 52w to assess TFC in all HD. A post-hoc analysis for the 45 mg bid dose was performed for TFC in early HD, and the dose was chosen for Phase 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of placebo matching pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Pridopidine 45 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Functional Capacity (TFC) From Baseline in Patients With Early HD (Defined as Patients With TFC&gt;=7)</title>
          <description>The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.</description>
          <population>FAS i.e. pts receiving ≥1 dose of study drug and with ≥1 post-BL efficacy assessment; pts with early HD defined by BL TFC score ≥7.&#xD;
The study tested 4 pridopidine doses on TMS for 26 w. Due to a new understanding on pridopidine's mechanism of action (S1R agonist), the study was extended to 52w to assess TFC in all HD. A post-hoc analysis for the 45 mg bid dose was performed for TFC in early HD, and the dose was chosen for Phase 3.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.22"/>
                    <measurement group_id="O2" value="-0.01" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Total Functional Capacity Responder Rate in Early HD</title>
        <description>The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning.&#xD;
Responder was defined as a TFC change to Week 52 of TFC&gt;=0.</description>
        <time_frame>52 weeks</time_frame>
        <population>FAS i.e. pts receiving ≥1 dose of study drug and with ≥1 post-BL efficacy assessment; pts with early HD defined by BL TFC score ≥7 who completed 52 weeks.&#xD;
The study tested 4 pridopidine doses on TMS for 26 w. Due to a new understanding on pridopidine's mechanism of action (S1R agonist), the study was extended to 52w to assess TFC in all HD. A post-hoc analysis for the 45 mg bid dose was performed for TFC in early HD, and the dose was chosen for Phase 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of placebo matching pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Pridopidine 45 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Functional Capacity Responder Rate in Early HD</title>
          <description>The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning.&#xD;
Responder was defined as a TFC change to Week 52 of TFC&gt;=0.</description>
          <population>FAS i.e. pts receiving ≥1 dose of study drug and with ≥1 post-BL efficacy assessment; pts with early HD defined by BL TFC score ≥7 who completed 52 weeks.&#xD;
The study tested 4 pridopidine doses on TMS for 26 w. Due to a new understanding on pridopidine's mechanism of action (S1R agonist), the study was extended to 52w to assess TFC in all HD. A post-hoc analysis for the 45 mg bid dose was performed for TFC in early HD, and the dose was chosen for Phase 3.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Tap-interval-MN-Hand, Early HD</title>
        <description>Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Tap-interval-MN-Hand, measured in seconds. Positive change from baseline indicates worsening.</description>
        <time_frame>26 and 52 weeks</time_frame>
        <population>FAS i.e. pts receiving &gt;=1 dose of study drug and with &gt;=1 post-BL efficacy assessment; pts with early HD defined by BL TFC score ≥7.&#xD;
The study tested 4 pridopidine doses on TMS for 26 w. Due to a new understanding on pridopidine's mechanism of action (S1R agonist), the study was extended to 52w to assess TFC in all HD. A post-hoc analysis for the 45 mg bid dose was performed for TFC in early HD, and the dose was chosen for Phase 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of placebo matching pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Pridopidine 45 mg BID</title>
            <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Tap-interval-MN-Hand, Early HD</title>
          <description>Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Tap-interval-MN-Hand, measured in seconds. Positive change from baseline indicates worsening.</description>
          <population>FAS i.e. pts receiving &gt;=1 dose of study drug and with &gt;=1 post-BL efficacy assessment; pts with early HD defined by BL TFC score ≥7.&#xD;
The study tested 4 pridopidine doses on TMS for 26 w. Due to a new understanding on pridopidine's mechanism of action (S1R agonist), the study was extended to 52w to assess TFC in all HD. A post-hoc analysis for the 45 mg bid dose was performed for TFC in early HD, and the dose was chosen for Phase 3.</population>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0247" spread="0.0118"/>
                    <measurement group_id="O2" value="-0.0096" spread="0.0110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0447" spread="0.0142"/>
                    <measurement group_id="O2" value="0.0003" spread="0.0150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0346</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>-0.0341</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0658</ci_lower_limit>
            <ci_upper_limit>-0.0026</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0305</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>-0.0444</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0847</ci_lower_limit>
            <ci_upper_limit>-0.0042</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Pridopidine matching placebo (hard capsules)&#xD;
Patients received a starting dose of pridopidine 22.5 mg or matching placebo and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 26.</description>
        </group>
        <group group_id="E2">
          <title>Pridopidine 45 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg (or matching placebo) and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 26.</description>
        </group>
        <group group_id="E3">
          <title>Pridopidine 67.5 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg (or matching placebo) and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 26.</description>
        </group>
        <group group_id="E4">
          <title>Pridopidine 90 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg (or matching placebo) and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 26.</description>
        </group>
        <group group_id="E5">
          <title>Pridopidine 112.5 mg BID</title>
          <description>Pridopidine given as hard capsules, twice daily&#xD;
Patients received a starting dose of pridopidine 22.5 mg (or matching placebo) and were during the first 4 weeks of treatment titrated to their randomised dose level. The randomised dose level was then to be maintained for the remainder of the treatment period through Week 26.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Urinary tetention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E4" events="17" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E5" events="15" subjects_affected="10" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="81"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="81"/>
                <counts group_id="E5" events="23" subjects_affected="15" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="31" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" events="44" subjects_affected="16" subjects_at_risk="81"/>
                <counts group_id="E3" events="31" subjects_affected="21" subjects_at_risk="82"/>
                <counts group_id="E4" events="19" subjects_affected="13" subjects_at_risk="81"/>
                <counts group_id="E5" events="42" subjects_affected="16" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" events="8" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" events="18" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E4" events="19" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Chorea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Data and results are owned by the sponsor. Results can be used by the institution for (a) internal noncommercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analyses for Early HD population were conducted as additional analyses</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prilenia</name_or_title>
      <organization>Prilenia</organization>
      <phone>+972 775558 ext 482</phone>
      <email>info@prilenia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

